GoodRx (NASDAQ:GDRX) Hits New 12-Month Low – Here’s Why

GoodRx Holdings, Inc. (NASDAQ:GDRX) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $2.40 and last traded at $2.3750, with a volume of 543404 shares. The stock had previously closed at $2.52.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GDRX. Morgan Stanley lowered their price objective on GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Jefferies Financial Group cut shares of GoodRx to a “hold” rating in a research report on Thursday, January 22nd. JPMorgan Chase & Co. cut their price objective on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Mizuho decreased their target price on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Finally, TD Cowen dropped their price target on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, GoodRx presently has an average rating of “Hold” and a consensus target price of $4.73.

GoodRx Trading Up 2.6%

The stock has a market cap of $814.63 million, a PE ratio of 13.00, a PEG ratio of 0.89 and a beta of 1.45. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock’s fifty day moving average price is $2.72 and its 200 day moving average price is $3.61.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million during the quarter, compared to the consensus estimate of $195.17 million. During the same period last year, the company posted $0.08 earnings per share. The business’s revenue was up .4% compared to the same quarter last year. On average, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Hedge Funds Weigh In On GoodRx

Several hedge funds and other institutional investors have recently bought and sold shares of GDRX. Vanguard Group Inc. grew its stake in shares of GoodRx by 7.3% in the third quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after acquiring an additional 624,182 shares during the period. Ameriprise Financial Inc. boosted its holdings in GoodRx by 4.0% in the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock worth $24,001,000 after purchasing an additional 184,734 shares during the last quarter. LSV Asset Management grew its position in GoodRx by 517.1% in the 3rd quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock worth $9,960,000 after purchasing an additional 1,973,017 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in GoodRx by 16.5% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock worth $8,324,000 after purchasing an additional 236,896 shares during the period. Finally, Pathway Capital Management LP raised its stake in GoodRx by 69.0% during the 3rd quarter. Pathway Capital Management LP now owns 986,158 shares of the company’s stock valued at $4,171,000 after buying an additional 402,721 shares during the last quarter. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.